Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Ponatinib Achieves Primary Endpoints in CML Subtypes

August 8th 2012

Ponatinib, an oral multikinase inhibitor, generated significant responses in more than 50% of patients with certain chronic myeloid leukemia subtypes.

Carfilzomib Shows Promise as Alternative to Bortezomib in Multiple Myeloma

August 2nd 2012

Two separate clinical trials presented at ASCO 2012 suggest that carfilzomib would be a safe and effective alternative to bortezomib for the treatment of multiple myeloma, following progression.

Dr. Rummel on the Chemical Structure of Bendamustine

July 30th 2012

Dr. Mathias Rummel, from the University Hospital Giessen in Germany, on the Bendamustine Chemical Structure

Researchers Share Honor for Bortezomib Discovery

July 27th 2012

Bortezomib represented a major discovery in cancer research and has helped some patients achieve a complete pathological response and live longer.

FDA Approves Carfilzomib for Relapsed Multiple Myeloma

July 23rd 2012

The FDA approved carfilzomib for patients with multiple myeloma who have received at least two prior lines of therapy.

Antibody-Drug Conjugates: Guided Missiles Deployed Against Cancerous Cells

July 5th 2012

Antibodies directed against tumor cell antigens or overexpressed proteins are currently the fastest-growing class of targeted cancer therapeutics.

Epigenetics Breathes New Life Into Older Cancer Drugs

June 22nd 2012

Cancer drugs once deemed too toxic for humans have earned a second chance at therapeutic utility, in part because of a reversal in the usual progression of medical research.

Hematology Pipeline: Baby Steps After a Giant Leap

June 21st 2012

A closer look at the hematology pipeline where there are multiple promising studies in progress for hematologic malignancies, including lymphoma, leukemia, and multiple myeloma.

ODAC Supports Carfilzomib for Relapsed Multiple Myeloma

June 20th 2012

ODAC voted 11-0 in support of carfilzomib as a new treatment option for patients with multiple myeloma, despite side effect concerns raised by the FDA.

There and Back…

June 15th 2012

One of my teachers in medical school was fond of saying, "Internal medicine isn't sexy." Hematology/ oncology is no exception to this rule. Certainly, it is not as glamorous as cardiology or as hands-on as gastroenterology.

Dr. Jorge Cortes Discusses the Ponatinib PACE Trial

June 14th 2012

Dr. Jorge Cortes, from the MD Anderson Cancer Center, Discusses the Ponatinib Ph+All and CML Evaluation (PACE) Trial

On the Horizon: Novel Inhibitors for Hematologic Malignancies

June 13th 2012

Increased understanding of the molecular mechanisms underlying the pathogenesis of hematologic cancers has led to the development of several promising new classes of targeted therapies.

JAK Pathway Yielding Results

June 13th 2012

JAK plays an important role in the formation and development of blood cells, and defects in the gene have been identified in myeloproliferative neoplasms.

Dr. Larsen Discusses Outcomes for AYA ALL Patients

June 7th 2012

Dr. Eric Larsen, from the Maine Children's Cancer Program, Discusses Outcomes for AYA Patients With Acute Lymphoblastic Leukemia

Dr. Rummel on Treanda Plus Rituxan in Indolent Lymphoma

June 3rd 2012

Dr. Mathias Rummel, from University Hospital Giessen in Germany, on Bendamustine Plus Rituximab in Indolent and Mantle Cell Lymphomas

Bendamustine Superiority in Lymphoma Regimen Confirmed

June 3rd 2012

Bendamustine should become the preferred chemotherapy standard of care in initial combination regimens for indolent lymphomas and mantle cell lymphoma.

Large Study of ALL Patients Finds Lower Survival in Adolescent and Young Adult Patients

June 2nd 2012

Adolescent and young adult patients between the ages of 16 and 30 had poorer outcomes when given the same treatment regimen as younger acute lymphoblastic leukemia patients.

Dr. Goy Highlights Research From the 2012 ASCO Meeting

May 30th 2012

Dr. Andre Goy, from John Theurer Cancer Center, Highlights Research From the 2012 ASCO Meeting.

ï»¿Photopheresis Process Offers Relief From Lymphoma Lesions: An Interview With Dennis Parenti, MD

May 24th 2012

To learn more about how photopheresis can help patients fight the symptoms of CTCL, OncologyLive spoke with Dennis Parenti, MD, vice president of Clinical Affairs for Therakos.

NCCN 17th Annual Conference: Clinical Practice Guidelines & Quality Cancer Care

May 23rd 2012

At this year's annual NCCN conference, the organization presented updates in 13 areas, including specific disease states and general screening methods.